GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Net-Net Working Capital

GlobeImmune (GlobeImmune) Net-Net Working Capital : $0.19 (As of Mar. 2016)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

GlobeImmune's Net-Net Working Capital for the quarter that ended in Mar. 2016 was $0.19.

The industry rank for GlobeImmune's Net-Net Working Capital or its related term are showing as below:

GBIM's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.18
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

GlobeImmune Net-Net Working Capital Historical Data

The historical data trend for GlobeImmune's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune Net-Net Working Capital Chart

GlobeImmune Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Net-Net Working Capital
Get a 7-Day Free Trial -1,926.95 -2,066.28 -2,091.83 0.70 0.24

GlobeImmune Quarterly Data
Dec10 Mar11 Jun11 Dec11 Mar12 Jun12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.29 0.32 0.24 0.19

Competitive Comparison of GlobeImmune's Net-Net Working Capital

For the Biotechnology subindustry, GlobeImmune's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeImmune's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where GlobeImmune's Price-to-Net-Net-Working-Capital falls into.



GlobeImmune Net-Net Working Capital Calculation

GlobeImmune's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2015 is calculated as

Net-Net Working Capital(A: Dec. 2015 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(9.901+0.75 * 0+0.5 * 0-8.518
-0-0)/5.75157
=0.24

GlobeImmune's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2016 is calculated as

Net-Net Working Capital(Q: Mar. 2016 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(8.694+0.75 * 0+0.5 * 0-7.621
-0-0)/5.75157
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


GlobeImmune  (OTCPK:GBIM) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


GlobeImmune Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines